• Se-Methylselenocysteine, NRF2, and Ferroptosis in PDAC

  2026-09-07

  A 2026 study shows that Se-methylselenocysteine reprograms NRF2-, ATF4-, redox-, and ferroptosis-associated pathways in pancreatic ductal adenocarcinoma cells in a KYAT1-dependent and phenotype-specific manner. Its findings define a framework for connecting selenium metabolism with oxidative stress adaptation and ferroptosis vulnerability in pancreatic cancer research.

• Cell Counting Kit-8 Plus: Mechanism and Workflow

  2026-09-05

  Cell Counting Kit-8 Plus is a sensitive tetrazolium salt assay for measuring viable-cell metabolic activity in proliferation, cytotoxicity, and drug-screening workflows. Its WST-8 chemistry provides a soluble formazan readout, while the linked ccRCC study shows why metabolic context must be considered when interpreting viability data.

• Netarsudil: ROCK Inhibition and siRNA Workflows

  2026-09-04

  Netarsudil (AR-13324) combines potent ROCK-pathway pharmacology with a distinctive opportunity for siRNA nanoparticle codelivery. This article translates that dual use-case into practical trabecular meshwork assays, formulation screens, controls, and troubleshooting decisions.

• Merbromin Inhibits SARS-CoV-2 3CLpro

  2026-09-04

  The reference study used activity-based high-throughput screening of approximately 6,000 compounds to identify Merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro. Enzyme kinetics, binding assays, and molecular docking supported a mixed-type mechanism involving two proposed binding sites, providing a starting point for antiviral inhibitor development.

• Ribociclib Succinate: From Arrest to Translation

  2026-09-03

  Ribociclib succinate is more than a selective CDK4/6 tool: it is a translational probe for connecting RB-dependent cell-cycle control with reproducible phenotypes, exposure design, and biomarker-informed cancer research. This article outlines how to move from LEE011 succinate mechanism to rigorous validation while avoiding unsupported cross-domain conclusions.

• Carvedilol Phosphate in Hepatic IRI Workflows

  2026-09-03

  Carvedilol Phosphate provides a practical, high-purity way to perturb adrenergic GPCR signaling in hepatocyte, macrophage, and ischemia–reperfusion assays. This guide connects compound handling and assay design with the Arrb2–6-ketoLCA findings of a recent liver IRI study while clearly separating established evidence from testable extensions.

• TRPM3 Regulation by Neurosteroids and Primidone

  2026-09-02

  Yin et al. combine cryo-EM structures, electrophysiology, molecular dynamics, and mass spectrometry to define how pregnenolone sulfate, CIM0216, and primidone regulate the TRPM3 channel. The study connects ligand-binding sites with channel gating and disease-associated gain-of-function mutations, providing a structural framework for analgesic and neurodevelopmental drug discovery.

• METTL16-SENP3-LTF Axis Drives HCC Ferroptosis Resistance

  2026-09-02

  Wang et al. identify METTL16 as an m6A-linked suppressor of ferroptosis in hepatocellular carcinoma and define a METTL16–IGF2BP2–SENP3–LTF pathway that controls iron availability. The study connects RNA modification, SUMO-dependent protein stability, and iron chelation to tumor progression, providing a mechanistic framework for ferroptosis-sensitization research.

• Bufalin–CRISPR Nanomedicine for CRC Immunotherapy

  2026-09-01

  The reference study develops a calcium lactate nanoparticle that co-delivers bufalin and a CRISPR/Cas9 ribonucleoprotein targeting CD47 to combine tumor-cell death with macrophage-mediated immunity. Its reported design links pH-responsive delivery, pyroptosis, apoptosis, M1 macrophage reprogramming, and enhanced phagocytosis, offering a preclinical strategy for colorectal cancer and metastatic disease.

• Protease Inhibitor Cocktail for Protein Integrity

  2026-09-01

  Protect labile proteins during tissue and cell disruption with an EDTA-free formulation designed for Western blotting, co-immunoprecipitation, pull-downs, and enzyme assays. Its 100X DMSO format supports reproducible dosing while avoiding chelation that can compromise phosphorylation analysis and metal-dependent enzymes.

• Losmapimod: p38 MAPK Assay Workflows

  2026-08-31

  Losmapimod enables controlled investigation of p38α/β-driven inflammation signaling, with workflows that connect kinase inhibition to phosphatase access, endothelial responses, and disease-relevant readouts. This guide emphasizes practical assay design, solvent control, orthogonal validation, and troubleshooting for vascular, hypertension, and COPD research.

• BML-277 Chk2 Inhibitor Workflow Guide

  2026-08-31

  BML-277 combines nanomolar biochemical potency with a practical path into T-cell radioprotection and DNA damage response research. This guide connects kinase assays, radiation-induced apoptosis workflows, and a hypothesis-driven Chk2–cGAS study design while emphasizing controls, solvent handling, and interpretation limits.

• (-)-Blebbistatin for Cardiac Mechanobiology

  2026-08-30

  Use (-)-Blebbistatin as a reversible non-muscle myosin II inhibitor to separate actomyosin-dependent force transmission from electrical and metabolic signals. Paired with transparent, stretchable microelectrode arrays, it enables more informative cardiac physiology, contractility, and cytoskeletal dynamics experiments.

• L-Alanyl-L-Glutamine: Practical Research Guide

  2026-08-29

  This guide provides a controlled workflow for evaluating L-Alanyl-L-Glutamine as an aqueous nutritional supplement dipeptide in gastrointestinal and intestinal-barrier research. It is appropriate for formulation development and exploratory in vitro testing, but the available dossier does not establish clinical efficacy, dosing, sterility, or a validated mechanism for a specific model.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance

  2026-08-28

  The reference study identifies RCN2 as a previously unrecognized driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance. Its mechanistic model connects RCN2 to UBR5-dependent PPP2CA degradation and subsequent PI3K-AKT pathway activation, suggesting a rationale for combining RCN2-directed strategies with cisplatin.

8143 records 5/543 page Previous Next 12345 下5页 Last page